Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, has expanded its collaboration with AmplifyBio, a rapidly growing contract development and manufacturing organization, through the installation of a new AVATAR Foundry system as part of Xcellbio’s beta access program.
AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.
The phase III comparative clinical trial for the investigational Perjeta (pertuzumab) biosimilar HLX11 met the primary endpoint of total pathological complete response rate.
A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.
FDA approved Opdivo (nivolumab) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent Opdivo after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
FDA granted traditional approval to Retevmo (selpercatinib) for adult and pediatric patients two years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
FDA approved the Cologuard Plus test, a multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are at average risk for colorectal cancer.
The National Cancer Institute approved the following clinical research studies last month.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
A law group associated with conservative causes and funded by leading conservative donors has sued NIH, HHS, and the National Library of Medicine, demanding that the institutions address PubMed’s inability to display all papers authored by researchers who have published under multiple names.
